跳转到主内容

非常抱歉,我们不完全支持您的浏览器。如果您可以选择,请升级到较新版本或使用 Mozilla Firefox、Microsoft Edge、Google Chrome 或 Safari 14 或更高版本。如果您无法进行此操作且需要支持,请将您的反馈发送给我们。

全新设计的官网为您带来全新体验,期待您的反馈

Elsevier
通过我们出版

Profile

Magdalini Polymenidou

Magdalini Polymenidou

University of Zürich, Switzerland

Magdalini Polymenidou is Associate Professor of Biomedicine at the Department of Quantitative Biomedicine of the University of Zurich (UZH). She is an expert on protein aggregation, prions and prion-like phenomena, as well as RNA-binding proteins. She joined UZH as an Assistant Professor in 2013 and her research team studies the molecular mechanisms of ALS and FTD with focus on the formation and properties of the physiological and pathological states of TDP-43 and FUS. Her team combines structural and biochemical analyses with cellular assays and animal models to identify new therapeutic targets from ALS and FTD. Originally trained as a pharmacist in Aristotle University of Thessaloniki (Greece), she did her PhD on prion diseases in the laboratory of Adriano Aguzzi at the University Hospital of Zurich (Switzerland). As a postdoctoral fellow in the group of Don Cleveland at the University of California in San Diego (USA), she used genome-wide approaches to understand the function of TDP-43 and FUS. Among other honors, she was elected an EMBO member (2025), received the Milken & Tambourine ALS Breakthrough Research Fund (2024), the ERC Consolidator Grant (2022), the NIBR Global Scholars Award (2022), the Franco Regli Prize (2019), the EMBO Young Investigator Award (2018), the Georg-Friedrich Götz Prize (2015), the SNSF Professorship (2013), the HFSP Career Development Award (2013) and the NIH Pathway to Independence Award (2011).